Reimbursement Still Missing Piece As Neuroscience Speeds Ahead

 
• By David Wild
  
Alzheimer's disease
Neuroscience is moving toward combination therapies that blend drugs, devices and digital tools, but reimbursement frameworks have no established pathway for multicomponent products. (Shutterstock)

More from Neurology

More from Strategy